⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148908 | 0.72 | — | — | |
| SCHEMBL11555466 | 0.67 | — | — | |
| SCHEMBL11663792 | 0.67 | — | — | |
| SCHEMBL4191989 | 0.67 | — | — | |
| SCHEMBL542914 | 0.67 | — | — | |
| SCHEMBL10355566 | 0.67 | — | — | |
| SCHEMBL8075789 | 0.67 | — | — | |
| SCHEMBL7931929 | 0.67 | — | — | |
| SCHEMBL11659827 | 0.67 | — | — | |
| Acetaldehyde SCHEMBL10068372 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| US-8580792-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-11-12 | — | — | US | disclosed |
| US-20130165449-A1 | Compounds and Method for Treatment of Cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-06-27 | — | — | US | disclosed |
| US-8420643-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-04-16 | — | — | US | disclosed |
| US-8367675-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-02-05 | — | — | US | disclosed |
| US-20120195887-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| US-20120077820-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-29 | — | — | US | disclosed |
| US-8138191-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-8034815-B2 | Imidazol-1-yl-(4-pyridin-2-yl-piperazin-1-yl)-methanethione; Critical Outcome Technologies' Iead compound (COTI); kinase inhibitor; anticarcinogenic agent; especially small cell lung cancer; cervical, ovarian, skin, prostate, breast, colorectal, head, neck, or kidney cancer, sarcoma, leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |